SciClone Pharmaceuticals, Inc.;FIRST AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY, A CHINESE UNIVERSITY HOSPITAL
发明人:
Xiangdong GUAN,Jianfeng WU,Cynthia W. TUTHILL
申请号：
US15710012
公开号：
US20180236036A1
申请日:
2017.09.20
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention provides methods for preventing, treating, or reducing the severity of sepsis, severe sepsis or septic shock, including bacterial, viral, and fungal infections, and including infections of more complex etiology. The invention involves the administration of an alpha thymosin peptide regimen. In certain embodiments, the alpha thymosin peptide regimen is scheduled or timed with respect to potential, expected and/or diagnosed sepsis, severe sepsis or septic shock. In certain embodiments, the patient is immunodeficient or immunecompromised, and/or the patient is hospitalized or scheduled for hospitalization, such that the regimen of alpha thymosin peptide peptide helps to protect the patient from, or reduce the severity of, sepsis, severe sepsis or septic shock.
